Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
01 Dicembre 2023 - 10:00PM
Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage
biotechnology company pioneering a new approach to the care of
cardiovascular disease with single-course gene editing medicines,
today announced the closing of its previously announced
underwritten public offering of 14,375,000 shares of its common
stock at a public offering price of $10.00 per share, which
includes 1,875,000 shares issued upon the exercise in full by the
underwriters of their option to purchase additional shares of
common stock at the public offering price, less underwriting
discounts and commissions. The total gross proceeds of the public
offering were approximately $143.8 million, before deducting
underwriting discounts and commissions and offering expenses
payable by Verve. All of the shares in the public offering were
sold by Verve.
In addition, Verve today announced the closing of its previously
announced private placement of 2,296,317 shares of its common stock
to Eli Lilly and Company, at a price per share equal to the public
offering price. The total gross proceeds of the private placement
were approximately $23.0 million.
Jefferies, Guggenheim Securities, William Blair, BMO Capital
Markets, and RBC Capital Markets acted as joint book-running
managers for the public offering.
The shares in the public offering were offered by
Verve pursuant to an automatically effective shelf registration
statement that was filed with the Securities and Exchange
Commission (“SEC”) on September 23, 2022. This public offering
was made only by means of a prospectus and prospectus supplement
that form a part of the registration statement. A final prospectus
supplement relating to and describing the terms of the public
offering has been filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and the accompanying prospectus may also be obtained by contacting:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, or by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com;
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, 8th Floor, New York, NY 10017, or by
telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com; William Blair
& Company, L.L.C., Attention: Prospectus Department, 150 North
Riverside Plaza, Chicago, IL 60606, or by telephone at
1-800-621-0687, or by email: prospectus@williamblair.com; or BMO
Capital Markets Corp., Attn: Equity Syndicate Department, 151 W
42nd Street, 32nd Floor, New York, NY 10036, or by email:
bmoprospectus@bmo.com; or RBC Capital Markets, LLC, Attention:
Equity Capital Markets, 200 Vesey Street, New York, NY 10281, or by
telephone at 877-822-4089 or by email at
equityprospectus@rbccm.com.
The shares sold in the concurrent private placement have not
been registered under the Securities Act of 1933, as amended (the
“Securities Act”), or any state or other applicable jurisdiction’s
securities laws, and may not be offered or sold in the United
States absent registration or an applicable exemption from the
registration requirements of the Securities Act and applicable
state or other jurisdictions’ securities laws.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Verve TherapeuticsVerve Therapeutics,
Inc. is a clinical-stage genetic medicines company pioneering a new
approach to the care of cardiovascular disease, potentially
transforming treatment from chronic management to single-course
gene editing medicines. The company’s initial three programs –
VERVE-101, VERVE-102, and VERVE-201 – target genes that have been
extensively validated as pharmacologic targets for lowering
low-density lipoprotein cholesterol (“LDL-C”), a root cause of
cardiovascular disease, in order to durably reduce blood LDL-C
levels.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Giu 2023 a Giu 2024